Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2017 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces First Quarter 2017 Financial Results

DURHAM, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results...
May 02, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017

DURHAM, N.C., May 02, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for...
April 20, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix to Host Annual Investor Update on April 27, 2017

DURHAM, N.C., April 20, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address...
March 02, 2017 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results

- Successful Administration of IV Brincidofovir 50 mg in Ongoing Dose Escalation Study -- Demonstrates Favorable Safety and Tolerability Profile -- Conference Call at 8:30 a.m. ET Today -DURHAM, N.C.,...
February 28, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Cowen and Company 37th Annual Health Care Conference

DURHAM, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address...
February 23, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017

DURHAM, N.C., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant,...
February 22, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings

-- Results show higher survival rate in adenovirus-infected patients with a virologic response to brincidofovir -- -- Mortality rates were lower in pediatric patients than in adult patients -- ...
January 06, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects

Study confirms drug levels for IV BCV 10 mg equivalent to oral BCV 100 mg No gastrointestinal side effects seen with IV BCV at 10 and 25 mg doses DURHAM, N.C., Jan. 06, 2017 (GLOBE...
January 05, 2017 16:01 ET | Source: Chimerix, Inc.

Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer

DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised...
January 04, 2017 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, today...